Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verrica Pharmaceuticals Inc
(NQ:
VRCA
)
2.330
-0.130 (-5.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,573,929
Open
2.440
Bid (Size)
2.330 (1)
Ask (Size)
2.390 (3)
Prev. Close
2.460
Today's Range
2.300 - 2.500
52wk Range
2.380 - 11.41
Shares Outstanding
41,957,197
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
August 27, 2024
Via
Benzinga
Crude Oil Down Over 1%; Mercury Systems Shares Spike Higher
August 14, 2024
Via
Benzinga
Exposures
Fossil Fuels
Performance
YTD
-65.79%
-65.79%
1 Month
-66.95%
-66.95%
3 Month
-72.33%
-72.33%
6 Month
-58.91%
-58.91%
1 Year
-48.39%
-48.39%
More News
Read More
Dow Jumps Over 200 Points; Performance Food Group Shares Gain After Q4 Results
August 14, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
August 14, 2024
Via
InvestorPlace
US Stocks Mixed; Inflation Rate Falls More Than Projected
August 14, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
August 14, 2024
Via
Benzinga
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 14, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
August 14, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
August 06, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
7 Short-Squeeze Stocks That Could Beat Down the Bears
July 15, 2024
Via
InvestorPlace
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
July 01, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
May 30, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 26, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
May 15, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
May 14, 2024
Via
Benzinga
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 13, 2024
Via
InvestorPlace
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
May 13, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
May 09, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
May 08, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 27, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
March 26, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
March 08, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
February 29, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.